• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: Bayer Pharma AG ESSURE; Transcervical Contraceptive Tubal Occlusion Device

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

Bayer Pharma AG ESSURE; Transcervical Contraceptive Tubal Occlusion Device Back to Search Results
Medical Device Problem Code Patient Device Interaction Problem (4001)
Health Effect - Clinical Codes Genital Bleeding (4507); Pelvic Pain (4865)
Type of Reportable Event Serious Injury
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ESSURE
Common Device Name
Transcervical Contraceptive Tubal Occlusion Device
Manufacturer (Section D)
Bayer Pharma AG
müllerstr. 178
berlin 13353
GM  13353
Manufacturer (Section G)
Bayer Pharma AG
müllerstr. 178
berlin 13353
GM   13353
Manufacturer Contact
janice miller
100 bayer blvd, p.o. box 915
whippany 07981--091
+1(862)404-3698
MDR Report Key50948230
Report Number2951250-2026-00295
Device Sequence Number9624065
Product Code HHS
UDI-Device Identifier10888853003051
UDI-Public10888853003051
Combination Product (Y/N)Y
Initial Reporter CountryUS
PMA/510(K) Number
P020014
Number of Events Summarized1
Summary Report (Y/N)N
Device Explanted Year2014
Reporter Type Manufacturer
Report Source Consumer
Type of Report Initial
Report Date (Section B) 09/30/2026
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Is the Reporter a Health Professional? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 09/28/2026
Initial Report FDA Received Date09/30/2026
Is the Device Labeled for Single Use? (Y/N) Yes
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention; Hospitalization;
Patient Age42 YR
Patient SexFemale
-
-